IP Library › Granted Patent US 9,040,038
Granted Patent B2
US 9,040,038 · App. 13/858,534 · Granted May 26, 2015

Modalities for the treatment of degenerative diseases of the retina

Inventors: Irina V. Klimanskaya (Upton, MA); Robert P. Lanza (Clinton, MA)
Assignee: Ocata Therapeutics, Inc.
C12N5/0621A61K35/12A61K35/44C12N5/062C12N2500/32C12N2500/44C12N2501/01C12N2501/115C12N2501/15C12N2501/155C12N2501/235C12N2501/33C12N2506/02A61K35/30A61K35/36A61K35/545C12N2501/60
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,040,038
App. No.
13/858,534
Granted
May 26, 2015
Kind
B2
Abstract

This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells.

Claims (7)

1. A method of producing a composition comprising isolated human RPE cells suitable for human therapy, comprising:

(a) culturing human pluripotent cells to form clusters of cells;

(b) culturing the clusters of cells of step (a) under adherent conditions that do not maintain the undifferentiated state of the pluripotent cells for a sufficient time for the appearance of pigmented cells comprising brown pigment dispersed in their cytoplasm; and

(c) isolating and culturing the pigmented cells to form a monolayer comprising cells having a cobblestone, polygonal, epithelial-like appearance and brown pigment dispersed in their cytoplasm, and expressing RPE65 and bestrophin, thereby obtaining human RPE cells.

2. The method of claim 1 wherein said clusters of cells of step (a) are trypsinized and cultured on adherent plates.

3. The method of claim 1 , wherein the monolayer of step (c) is dissociated to form a suspension of RPE cells suitable for subretinal transplantation in a human patient.

4. The method of claim 1 , wherein the monolayer of step (c) is disposed on a matrix or substrate to form a monolayer of RPE cells suitable for subretinal transplantation in a human patient.

Assignments (5)
CONFIRMATORY ASSIGNMENT Recorded Apr 5, 2024
From: ASTELLAS INSTITUTE FOR REGENERATIVE MEDICINE
To: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Reel/Frame 067024/0057 →
CHANGE OF NAME Recorded Jul 27, 2016
From: OCATA THERAPEUTICS, INC.
To: ASTELLAS INSTITUTE FOR REGENERATIVE MEDICINE
Reel/Frame 039493/0166 →
CHANGE OF NAME Recorded Feb 13, 2015
From: ADVANCED CELL TECHNOLOGY, INC.
To: OCATA THERAPEUTICS, INC.
Reel/Frame 034999/0826 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 23, 2014
From: KLIMANSKAYA, IRINA V.
To: ADVANCED CELL TECHNOLOGY, INC.
Reel/Frame 034023/0115 →
CONFIRMATORY ASSIGNMENT Recorded Oct 23, 2014
From: LANZA, ROBERT
To: ADVANCED CELL TECHNOLOGY, INC.
Reel/Frame 034038/0172 →
Continuity (5)
Continuation 13477763 · May 22, 2012
Continuation 12857911 · Aug 17, 2010
Continuation 11041382 · Jan 24, 2005
Provisional Application 60538964 · Jan 23, 2004
Related Publication 20130316452A1 · Nov 28, 2013